Potential Clinical Utility of Niacin Skin Test and FACS-Based GPR109A Evaluation as a Combined Discriminatory Tool for Treatment-Resistant Schizophrenia
The Tohoku Journal of Experimental Medicine · 2026 · 270 (1) · 149-158
DOI: 10.1620/tjem.2026.j006 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2026. Verfasst von Tai-Yuan Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University. Hauptthemen laut MEDLINE: Niacin, Receptors, G-Protein-Coupled, Flow Cytometry, Schizophrenia, Treatment-Resistant. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Several studies have suggested that an abnormal niacin-induced flush response may serve as a stable biomarker for schizophrenia. This response is mediated by the G-protein-coupled receptor 109A (GPR109A). Treatment-resistant schizophrenia (TRS) patients typically exhibit more severe psychopathology; however, the molecular mechanisms underlying niacin-mediated signaling in TRS remain unclear. This study aimed to evaluate the potential of the niacin response and GPR109A as biomarkers for TRS. We examined 19 patients with TRS, 24 patients with non-TRS, and 37 healthy controls (HC). GPR109A expression on monocytes was measured using flow cytometry. Receiver operating characteristic (ROC) curve analysis and support vector machine (SVM) were used for evaluating the classified efficiency of the combined niacin flush response and GPR109A expression. TRS tended to have attenuated niacin flush response and lower levels of GPR109A expression than non-TRS and HC. In the ROC curve analysis based on logistic regression, the area under the curve (AUC) for the combined representative score of niacin flush response and GPR109A expression was 0.98 for TRS vs. HC, 0.88 for non-TRS vs. HC, and 0.76 for TRS vs. non-TRS. Using an SVM classifier, the AUC for the combined markers in distinguishing TRS from non-TRS was 0.86. Our findings indicate that the combined assessment of niacin flush response and GPR109A expression could discriminate between TRS and non-TRS cases. These markers may therefore serve as predictive tools for identifying schizophrenia patients in whom clinical assessment alone is inconclusive, thereby facilitating early recognition of those at risk of developing TRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University.
- Department of Psychiatry, Chi Mei Medical Center.
- Department of Psychiatry, Yo-Chin Foundation Yo-Chin Hospital.
- Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University.
- Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University.
- Department of Public Health, College of Medicine, National Cheng Kung University.
Zitieren
APA
Lin, T. Y., Lin, J. J., Tseng, H. H., Jang, F. L., Chen, P. S., & Lin, S. H. (2026). Potential Clinical Utility of Niacin Skin Test and FACS-Based GPR109A Evaluation as a Combined Discriminatory Tool for Treatment-Resistant Schizophrenia. The Tohoku Journal of Experimental Medicine, 270(1), 149-158. https://doi.org/10.1620/tjem.2026.j006
Vancouver
Lin TY, Lin JJ, Tseng HH, Jang FL, Chen PS, Lin SH. Potential Clinical Utility of Niacin Skin Test and FACS-Based GPR109A Evaluation as a Combined Discriminatory Tool for Treatment-Resistant Schizophrenia. The Tohoku Journal of Experimental Medicine. 2026;270(1):149-158. doi:10.1620/tjem.2026.j006
BibTeX
@article{Lin2026,
author = {Lin, Tai-Yuan and Lin, Jin-Jia and Tseng, Huai-Hsuan and Jang, Fong-Lin and Chen, Po-See and Lin, Sheng-Hsiang},
title = {Potential Clinical Utility of Niacin Skin Test and FACS-Based GPR109A Evaluation as a Combined Discriminatory Tool for Treatment-Resistant Schizophrenia},
journal = {The Tohoku Journal of Experimental Medicine},
year = {2026},
volume = {270},
number = {1},
pages = {149--158},
doi = {10.1620/tjem.2026.j006}
}
EUVIMED